Cetuximab sarotalocan

Cetuximab sarotalocan (Cetuximab-IRDye-700DX) is an IRdye700DX (near-infrared photosensitizing dye) conjugate of Cetuximab (anti-EGFR monoclonal antibody). Cetuximab sarotalocan can be used for head and neck cancers research[1][2].

Research Areas >> Cancer

Signaling Pathways >> JAK/STAT Signaling >> EGFR

Signaling Pathways >> Protein Tyrosine Kinase/RTK >> EGFR

Cetuximab sarotalocan sodium is formed by an antibody-photosensitive complex that combines Cetuximab, an epidermal growth factor receptor monoclonal antibody, with the dye IRdye700DX, a photosensitive substance. After administration of Cetuximab sarotalocan sodium, only tumor cells are specifically destroyed by illumination with a red light at 690 nm[2].

[1]. Go Omura, et al. Transnasal photoimmunotherapy with cetuximab sarotalocan sodium: Outcomes on the local recurrence of nasopharyngeal squamous cell carcinoma. Auris Nasus Larynx. 2022 Jun 29;S0385-8146(22)00167-5.  

[2]. Isaku Okamoto, et al. Quality-of-Life Evaluation of Patients with Unresectable Locally Advanced or Locally Recurrent Head and Neck Carcinoma Treated with Head and Neck Photoimmunotherapy. Cancers (Basel). 2022 Sep 11;14(18):4413.